Business
Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, including programs using its Alector Brain Carrier platform.
Alector revenue fell 79.1% to $21.0M, net loss widened to $142.9M, and equity fell 75.8%.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage neurodegeneration biotechWatch
- Revenue — Revenue fell 79.1% to $21.0MWatch
- Cash — Free cash flow improved but stayed -$184.1MNote
- Profitability — Net loss widened to $142.9MWatch
- Balance sheet — Equity fell 75.8%Watch
- Insiders — 0 buys / 17 sellsWatch
- Accounting — Altman-Z distress; other scores unavailableWatch
Leadership changes
From Alector, Inc.'s own filings, the day they're filed.
- Neil Berkley · Chief Financial Officer · appointmenteff. 2025-12-10
- Terry McGuire · member · departureeff. 2024-03-15
- Errol De Souza · director · appointment
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-08
- 8-K · Company announcement2026-06-17
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Alector, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.